Altimmune, Inc.
US ˙ NasdaqGM ˙ US02155H2004

Introduction

This page provides a comprehensive analysis of the known insider trading history of David Drutz. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate David Drutz has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:ALT / Altimmune, Inc. Director 55,524
US:DARA / DARA Biosciences, Inc. Executive Chairman and CMO, Director 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by David Drutz. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases ALT / Altimmune, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ALT / Altimmune, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2023-08-15 ALT Drutz David 300 2.8750 300 2.8750 862 196 13.8100 3,281 380.63
2023-03-23 ALT Drutz David 9,000 4.2700 9,000 4.2700 38,430
2022-06-15 ALT Drutz David 1,000 8.0000 1,000 8.0000 8,000
2022-05-24 ALT Drutz David 1,200 4.5000 1,200 4.5000 5,400
2017-08-23 ALT Drutz David 5,000 2.2679 167 68.0370 11,340
2017-08-22 ALT Drutz David 5,000 2.1515 167 64.5450 10,758

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ALT / Altimmune, Inc. Insider Trades
Insider Sales ALT / Altimmune, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ALT / Altimmune, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2024-08-19 ALT Drutz David 7,827 6.9300 7,827 6.9300 54,241 357 3.3800 -27,786 -51.23
2024-08-19 ALT Drutz David 8,184 6.8800 8,184 6.8800 56,306

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ALT / Altimmune, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by David Drutz as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2024-08-20 2024-08-19 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
S - Sale -8,184 55,524 -12.85 6.88 -56,306 382,005
2024-08-20 2024-08-19 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
M - Exercise 21,750 63,708 51.84 2.50 54,375 159,270
2024-08-20 2024-08-19 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
S - Sale -7,827 41,958 -15.72 6.93 -54,241 290,769
2024-08-20 2024-08-19 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
M - Exercise 20,000 49,785 67.15 2.60 52,000 129,441
2023-08-15 2023-08-15 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
P - Purchase 300 29,785 1.02 2.88 862 85,632
2023-03-27 2023-03-23 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
P - Purchase 9,000 29,484 43.94 4.27 38,430 125,897
2022-11-21 2022-11-18 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
M - Exercise 139 20,151 0.69 2.40 334 48,362
2022-06-16 2022-06-15 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
P - Purchase 1,000 20,012 5.26 8.00 8,000 160,096
2022-05-25 2022-05-24 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
P - Purchase 1,200 19,012 6.74 4.50 5,400 85,554
2022-02-16 2017-05-04 4/A ALT Altimmune, Inc.
Stock Options (option to buy)
A - Award 139 139
2022-02-16 2017-05-04 4/A ALT Altimmune, Inc.
Stock Options (option to buy)
A - Award 139 139
2022-01-26 2022-01-25 4 ALT Altimmune, Inc.
Stock Options (option to buy)
M - Exercise -70 69 -50.36
2022-01-26 2022-01-25 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
M - Exercise 70 17,882 0.39 2.40 168 42,917
2021-12-15 2021-12-14 4 ALT Altimmune, Inc.
Stock Options (option to buy)
M - Exercise -139 0 -100.00
2021-12-15 2021-12-14 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
M - Exercise 139 17,812 0.79 2.40 334 42,749
2021-11-19 2021-11-19 4 ALT Altimmune, Inc.
Stock Options (option to buy)
M - Exercise -70 0 -100.00
2021-11-19 2021-11-19 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
M - Exercise 70 17,673 0.40 2.40 168 42,415
2021-09-24 2021-09-23 4 ALT Altimmune, Inc.
Stock Options (option to buy)
A - Award 24,100 24,100
2020-11-17 2020-11-13 4 ALT Altimmune, Inc.
Stock Options (option to buy)
M - Exercise -60 0 -100.00
2020-11-17 2020-11-13 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
M - Exercise 60 17,603 0.34 2.40 144 42,247
2020-10-16 2020-09-24 4 ALT Altimmune, Inc.
Restricted Stock Units ("RSUs")
M - Exercise -16,850 0 -100.00
2020-10-16 2020-09-24 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
M - Exercise 16,850 17,543 2,431.46
2020-09-28 2020-09-24 4 ALT Altimmune, Inc.
Stock Options (option to buy)
A - Award 25,500 25,500
2020-06-29 2020-06-25 4 ALT Altimmune, Inc.
Restricted Stock Units ("RSUs")
A - Award 16,850 16,850
2019-01-04 2019-01-02 4 ALT Altimmune, Inc.
Stock Options (option to buy)
A - Award 20,000 20,000
2017-10-17 2017-10-13 4 ALT Altimmune, Inc.
Stock Options (option to buy)
A - Award 20,000 20,000
2017-08-24 2017-08-23 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
P - Purchase 5,000 30,777 19.40 2.27 11,340 69,799
2017-08-24 2017-08-22 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
P - Purchase 5,000 25,777 24.07 2.15 10,758 55,459
2017-05-08 2017-05-04 4 NASDAQ:ALT Altimmune, Inc.
Stock Option (option to buy)
A - Award 4,177 4,177
2017-05-08 2017-05-04 4 NASDAQ:ALT Altimmune, Inc.
Stock Option (option to buy)
A - Award 4,178 4,178
2017-05-08 2017-05-04 4 NASDAQ:ALT Altimmune, Inc.
Stock Option (option to buy)
A - Award 4,178 4,178
2017-05-08 2017-05-04 4 NASDAQ:ALT Altimmune, Inc.
Stock Option (option to buy)
A - Award 2,090 2,090
2017-05-08 2017-05-04 4 NASDAQ:ALT Altimmune, Inc.
Stock Option (option to buy)
A - Award 1,791 1,791
2017-05-08 2017-05-04 4 NASDAQ:ALT Altimmune, Inc.
Stock Option (option to buy)
A - Award 1,791 1,791
2017-05-08 2017-05-04 4 NASDAQ:ALT Altimmune, Inc.
Stock Option (option to buy)
A - Award 4,755 4,755
2017-05-08 2017-05-04 4 NASDAQ:ALT Altimmune, Inc.
Common Stock, par value $0.0001
A - Award 20,777 20,777
2015-12-07 2015-12-04 4 DARA Midatech Pharma US Inc.
Warrants
D - Sale to Issuer -22,523 0 -100.00
2015-12-07 2015-12-04 4 DARA Midatech Pharma US Inc.
Preferred Stock
D - Sale to Issuer -50 0 -100.00
2015-12-07 2015-12-04 4 DARA Midatech Pharma US Inc.
Stock Option
D - Sale to Issuer -80,000 0 -100.00
2015-12-07 2015-12-04 4 DARA Midatech Pharma US Inc.
Stock Option
D - Sale to Issuer -80,000 0 -100.00
2015-12-07 2015-12-04 4 DARA Midatech Pharma US Inc.
Stock Option
D - Sale to Issuer -371,000 0 -100.00
2015-12-07 2015-12-04 4 DARA Midatech Pharma US Inc.
Stock Option
D - Sale to Issuer -100,000 0 -100.00
2015-12-07 2015-12-04 4 DARA Midatech Pharma US Inc.
Stock Option
D - Sale to Issuer -43,333 0 -100.00
2015-12-07 2015-12-04 4 DARA Midatech Pharma US Inc.
Stock Option
D - Sale to Issuer -10,000 0 -100.00
2015-12-07 2015-12-04 4 DARA Midatech Pharma US Inc.
Stock Option
D - Sale to Issuer -75,000 0 -100.00
2015-12-07 2015-12-04 4 DARA Midatech Pharma US Inc.
Stock Option
D - Sale to Issuer -2,000 0 -100.00
2015-12-07 2015-12-04 4 DARA Midatech Pharma US Inc.
Stock Option
D - Sale to Issuer -1,000 0 -100.00
2015-12-07 2015-12-04 4 DARA Midatech Pharma US Inc.
Stock Option
D - Sale to Issuer -375 0 -100.00
2015-12-07 2015-12-04 4 DARA Midatech Pharma US Inc.
Common Stock
D - Sale to Issuer -20,614 0 -100.00
2015-05-20 2015-05-19 4 DARA DARA BioSciences, Inc.
Stock Option (right to buy)
A - Award 80,000 80,000
2015-02-09 2015-02-09 4 DARA DARA BioSciences, Inc.
Stock Option (right to buy)
A - Award 371,000 371,000
2014-06-05 2014-06-04 4 DARA DARA BioSciences, Inc.
Common Stock Purchase Warrants (right to buy)
P - Purchase 22,523 22,523
2014-06-05 2014-06-04 4 DARA DARA BioSciences, Inc.
Common Stock Purchase Warrants (right to buy)
P - Purchase 22,523 22,523
2014-06-05 2014-06-04 4 DARA DARA BioSciences, Inc.
Series C-1 Convertible Preferred Stock
P - Purchase 50 50
2014-03-06 2014-03-04 4 DARA DARA BioSciences, Inc.
Stock Option (right to buy)
A - Award 100,000 100,000
2013-05-20 2013-05-17 4 DARA DARA BioSciences, Inc.
Common Stock
P - Purchase 25,000 103,072 32.02 0.70 17,440 71,903
2013-03-04 2013-02-28 4 DARA DARA BioSciences, Inc.
Stock Option (right to buy)
A - Award 400,000 400,000
2013-01-22 2013-01-18 4 DARA DARA BioSciences, Inc.
Stock Option (right to buy)
A - Award 216,666 216,666
2012-09-17 2012-09-17 4 DARA DARA BioSciences, Inc.
Common Stock
P - Purchase 25,000 78,073 47.10 1.06 26,500 82,757
2012-06-11 2012-06-08 4 DARA DARA BioSciences, Inc.
Common Stock
P - Purchase 25,000 53,073 89.05 0.77 19,250 40,866
2012-05-30 2012-05-29 4 DARA DARA BioSciences, Inc.
Common Stock
P - Purchase 25,000 28,073 813.54 0.90 22,532 25,302
2012-05-17 2012-05-15 4 DARA DARA BioSciences, Inc.
Stock Option (right to buy)
A - Award 50,000 50,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)